insulin aspart vs Insulin Lispro

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline

insulin aspart · NovoLog

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2028 · NCT07652528 (registry estimate)

No aligned efficacy figure on record for this race.

Insulin Lispro · Humalog

Marketed by Eli Lilly

Approved in Type 2 Diabetespeptide
Reliable signal

NCT01474538 · Phase 3 · completed

The study randomized 122 participants to receive both insulin lispro and insulin aspart in crossover order, with participants, investigators, and outcome assessors masked. Its primary clinical endpoint, HbA1c after 16 weeks, met the prespecified non-inferiority criterion for lispro versus aspart, with the upper confidence limit below the 0.4% margin.

Next expected readout: December 2026 · NCT06251635 (registry estimate)

Reported efficacy

Glycosylated Hemoglobin A1C (HbA1c) at Endpoint (After 16 weeks of each treatment (Periods1 and 2)): Glycosylated Hemoglobin A1C (HbA1c) at Endpoint (After 16 weeks of each treatment (Periods1 and 2)): Insulin Lispro 7.5 percentage of glycosylated hemoglobin (Standard Error 0.12) | Insulin Aspart 7.4 percentage of glycosylated hemoglobin (Standard Error 0.12) (met)

Result source: NCT01474538

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinsulin aspartInsulin Lispro
HbA1c, change-1.2% vs -1.3%vs IGlaronce daily · wk 52 · n 744NCT00972283
19 other results
  • -1.2% vs -1.2% wk 26 · n 291 · Phase 3 · primary NCT04880850
  • -1.5% vs -1.4% BID · wk 26 · n 359 · Phase 3 · primary NCT02762578
  • -1.9% vs -1.7% wk 26 · n 197 · Phase 3 · primary NCT01513590
  • -1.4% vs -1.4% BID · wk 26 · n 280 · Phase 3 · primary NCT01059812
  • -0.7% vs 0.1% wk 26 · n 88 · Phase 3 · primary NCT01388361
  • -1.4% vs -1.2% OD · wk 26 · n 147 · Phase 3 · primary NCT01272193
  • -1.0% vs -1% once daily · wk 26 · n 230 · Phase 3 · primary NCT01045447
  • -1.6% vs -1.7% wk 26 · n 266 · Phase 3 · primary NCT01045707
  • -1.3% vs -1.3% wk 26 · n 224 · Phase 3 · primary NCT01009580
  • -1.1% vs -1.1% twice daily · wk 4.14 · n 121 · Phase 3 · primary NCT02648217
  • -1.4% vs -1.3% wk 53 · n 266 · Phase 3 · secondary NCT01045707
  • -0.9% vs -1.1% once daily · wk 78 · n 744 · Phase 3 · secondary NCT00972283
  • -1.2% vs -1.3% wk 32 · n 164 · Phase 4 · primary NCT02453685
  • -1.0% vs -1.1% wk 32 · n 195 · Phase 4 · primary NCT01165684
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
  • 4.1% vs 3.4% wk 26 · n 46 · Phase 4 · primary NCT01966978
  • -0.5% vs -0.5% n 115 · Phase 2 · primary NCT01194258
  • -0.8% vs -1.1% wk 21 · n 195 · Phase 4 · secondary NCT01165684
  • -0.5% vs -1% wk 10 · n 193 · Phase 4 · secondary NCT01165684
-1.2% vs -1.1%vs Insulin Glargine1.5 mg · wk 26 · n 138NCT01621178
20 other results
  • -1.6% vs -1.4% 1.5 mg · wk 26 · n 273 · Phase 3 · primary NCT01191268
  • -1.1% vs -1.1% 0.75 mg · wk 26 · n 149 · Phase 3 · primary NCT01621178
  • -1.6% vs -1.4% 0.75 mg · wk 26 · n 275 · Phase 3 · primary NCT01191268
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.0% vs -1.1% wk 26 · n 345 · Phase 3 · primary NCT02229227
  • -1.7% vs -1.4% wk 26 · n 684 · Phase 3 · primary NCT01468987
  • -1.2% vs -1.3% wk 24 · n 148 · Phase 3 · primary NCT00666718
  • -1.5% vs -1.2% 1.5 mg · wk 52 · n 273 · Phase 3 · secondary NCT01191268
  • -1.4% vs -1.2% 0.75 mg · wk 52 · n 275 · Phase 3 · secondary NCT01191268
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -1.0% vs -1.1% wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1% vs -1.3% wk 24 · n 179 · Phase 3 · secondary NCT00666718
  • -1.0% vs -1.1% wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -0.9% vs -1.0% wk 12 · n 179 · Phase 3 · secondary NCT00666718
  • -0.9% vs -1.0% wk 10 · n 402 · Phase 3 · secondary NCT02229227
  • -0.7% vs -0.6% wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -0.6% vs -0.5% wk 4 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1% vs -1% 1.5 mg · wk 52 · n 130 · Phase 3 · secondary NCT01621178
  • -1.1% vs -1% 0.75 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1% vs -0.8% wk 16 · n 131 · Phase 4 · secondary NCT00393705
Body weight, change (kg)2.7 vs 2.2vs Insulin Glarginewk 26 · n 291NCT04880850
11 other results
  • 2.8 vs 2.2 BID · wk 26 · n 359 · Phase 3 · secondary NCT02762578
  • 2.8 vs 2 wk 26 · n 196 · Phase 3 · secondary NCT01513590
  • -1 vs 0.1 wk 26 · n 87 · Phase 3 · secondary NCT01388361
  • 0.7 vs 0.7 OD · wk 26 · n 147 · Phase 3 · secondary NCT01272193
  • 1.1 vs 1.4 BID · wk 26 · n 279 · Phase 3 · secondary NCT01059812
  • 0.9 vs 0.3 wk 16 · n 117 · Phase 3 · secondary NCT01474538
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
  • -0.6 vs 3.1 wk 26 · n 46 · Phase 4 · secondary NCT01966978
  • 1.5 vs 1.6 n 115 · Phase 2 · secondary NCT01194258
  • 0.3 vs 0.8 wk 26 · n 22 · Phase 4 · secondary NCT00998335
  • 0.1 vs -0.1 wk 6 · n 33 · Phase 2 · secondary NCT00842361
-2.8 vs 1.1vs Insulin Glargine1.5 mg · wk 26 · n 140NCT01621178
15 other results
  • -2.0 vs 1.1 0.75 mg · wk 26 · n 151 · Phase 3 · secondary NCT01621178
  • -1.7 vs 1.6 0.75 mg · wk 52 · n 137 · Phase 3 · secondary NCT01621178
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • -1.9 vs 2.4 wk 26 · n 349 · Phase 3 · secondary NCT02229227
  • -1.9 vs 2.4 wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • 1.3 vs 2.2 wk 26 · n 682 · Phase 3 · secondary NCT01468987
  • 1.0 vs 1.2 wk 24 · n 187 · Phase 3 · secondary NCT00666718
  • -2.0 vs 2.1 wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -1.7 vs 1.5 wk 10 · n 402 · Phase 3 · secondary NCT02229227
  • -0.9 vs 0.8 wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -0.6 vs 0.7 wk 4 · n 402 · Phase 3 · secondary NCT02229227
  • -2.7 vs 1.6 1.5 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • 0.3 vs 0.9 wk 16 · n 116 · Phase 3 · secondary NCT01474538
  • 1.3 vs 0.4 wk 16 · n 126 · Phase 4 · secondary NCT00393705
  • 2.6 vs 2.7 wk 48 · n 138 · Phase 4 · secondary NCT00664534
HbA1c below 7%44% vs 20%vs Metformin, Insulin Detemir, Insulin Aspartwk 26 · n 46NCT0196697837.5% vs 34.6%vs Insulin Glargine1.5 mg · wk 26 · n 152NCT01621178
3 other results
  • 32.9% vs 29.1% 1.5 mg · wk 52 · n 152 · Phase 3 · secondary NCT01621178
  • 31.7% vs 34.6% 0.75 mg · wk 26 · n 164 · Phase 3 · secondary NCT01621178
  • 33.5% vs 29.1% 0.75 mg · wk 52 · n 164 · Phase 3 · secondary NCT01621178
Fasting plasma glucose, change-1.8 vs -1.6vs Insulin Glarginewk 26 · n 283NCT04880850
5 other results
  • -3.0 vs -1.6 BID · wk 26 · n 354 · Phase 3 · secondary NCT02762578
  • -4.4 vs -3.0 wk 26 · n 195 · Phase 3 · secondary NCT01513590
  • -0.1 vs -1.2 wk 26 · n 86 · Phase 3 · secondary NCT01388361
  • -2 vs -4.4 twice daily · wk 4.14 · n 115 · Phase 3 · secondary NCT02648217
  • 6.4 vs 4.9 wk 26 · n 22 · Phase 4 · secondary NCT00998335
-2.0 vs -1.5vs Insulin Lispro + Insulin Glarginewk 26 · n 345NCT02229227
4 other results
  • -2.0 vs -1.5 wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • -1.8 vs -1.2 wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1 vs -0.9 wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -1.3 vs -0.8 wk 4 · n 402 · Phase 3 · secondary NCT02229227
3-point MACE (% with event)—Not posted · NCT01467323—Not posted · NCT00551356

HbA1c, change

insulin aspart
-1.2% vs -1.3%vs IGlaronce daily · wk 52 · n 744NCT00972283
19 other results
  • -1.2% vs -1.2% wk 26 · n 291 · Phase 3 · primary NCT04880850
  • -1.5% vs -1.4% BID · wk 26 · n 359 · Phase 3 · primary NCT02762578
  • -1.9% vs -1.7% wk 26 · n 197 · Phase 3 · primary NCT01513590
  • -1.4% vs -1.4% BID · wk 26 · n 280 · Phase 3 · primary NCT01059812
  • -0.7% vs 0.1% wk 26 · n 88 · Phase 3 · primary NCT01388361
  • -1.4% vs -1.2% OD · wk 26 · n 147 · Phase 3 · primary NCT01272193
  • -1.0% vs -1% once daily · wk 26 · n 230 · Phase 3 · primary NCT01045447
  • -1.6% vs -1.7% wk 26 · n 266 · Phase 3 · primary NCT01045707
  • -1.3% vs -1.3% wk 26 · n 224 · Phase 3 · primary NCT01009580
  • -1.1% vs -1.1% twice daily · wk 4.14 · n 121 · Phase 3 · primary NCT02648217
  • -1.4% vs -1.3% wk 53 · n 266 · Phase 3 · secondary NCT01045707
  • -0.9% vs -1.1% once daily · wk 78 · n 744 · Phase 3 · secondary NCT00972283
  • -1.2% vs -1.3% wk 32 · n 164 · Phase 4 · primary NCT02453685
  • -1.0% vs -1.1% wk 32 · n 195 · Phase 4 · primary NCT01165684
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
  • 4.1% vs 3.4% wk 26 · n 46 · Phase 4 · primary NCT01966978
  • -0.5% vs -0.5% n 115 · Phase 2 · primary NCT01194258
  • -0.8% vs -1.1% wk 21 · n 195 · Phase 4 · secondary NCT01165684
  • -0.5% vs -1% wk 10 · n 193 · Phase 4 · secondary NCT01165684
Insulin Lispro
-1.2% vs -1.1%vs Insulin Glargine1.5 mg · wk 26 · n 138NCT01621178
20 other results
  • -1.6% vs -1.4% 1.5 mg · wk 26 · n 273 · Phase 3 · primary NCT01191268
  • -1.1% vs -1.1% 0.75 mg · wk 26 · n 149 · Phase 3 · primary NCT01621178
  • -1.6% vs -1.4% 0.75 mg · wk 26 · n 275 · Phase 3 · primary NCT01191268
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.0% vs -1.1% wk 26 · n 345 · Phase 3 · primary NCT02229227
  • -1.7% vs -1.4% wk 26 · n 684 · Phase 3 · primary NCT01468987
  • -1.2% vs -1.3% wk 24 · n 148 · Phase 3 · primary NCT00666718
  • -1.5% vs -1.2% 1.5 mg · wk 52 · n 273 · Phase 3 · secondary NCT01191268
  • -1.4% vs -1.2% 0.75 mg · wk 52 · n 275 · Phase 3 · secondary NCT01191268
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -1.0% vs -1.1% wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1% vs -1.3% wk 24 · n 179 · Phase 3 · secondary NCT00666718
  • -1.0% vs -1.1% wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -0.9% vs -1.0% wk 12 · n 179 · Phase 3 · secondary NCT00666718
  • -0.9% vs -1.0% wk 10 · n 402 · Phase 3 · secondary NCT02229227
  • -0.7% vs -0.6% wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -0.6% vs -0.5% wk 4 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1% vs -1% 1.5 mg · wk 52 · n 130 · Phase 3 · secondary NCT01621178
  • -1.1% vs -1% 0.75 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1% vs -0.8% wk 16 · n 131 · Phase 4 · secondary NCT00393705

Body weight, change (kg)

insulin aspart
2.7 vs 2.2vs Insulin Glarginewk 26 · n 291NCT04880850
11 other results
  • 2.8 vs 2.2 BID · wk 26 · n 359 · Phase 3 · secondary NCT02762578
  • 2.8 vs 2 wk 26 · n 196 · Phase 3 · secondary NCT01513590
  • -1 vs 0.1 wk 26 · n 87 · Phase 3 · secondary NCT01388361
  • 0.7 vs 0.7 OD · wk 26 · n 147 · Phase 3 · secondary NCT01272193
  • 1.1 vs 1.4 BID · wk 26 · n 279 · Phase 3 · secondary NCT01059812
  • 0.9 vs 0.3 wk 16 · n 117 · Phase 3 · secondary NCT01474538
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
  • -0.6 vs 3.1 wk 26 · n 46 · Phase 4 · secondary NCT01966978
  • 1.5 vs 1.6 n 115 · Phase 2 · secondary NCT01194258
  • 0.3 vs 0.8 wk 26 · n 22 · Phase 4 · secondary NCT00998335
  • 0.1 vs -0.1 wk 6 · n 33 · Phase 2 · secondary NCT00842361
Insulin Lispro
-2.8 vs 1.1vs Insulin Glargine1.5 mg · wk 26 · n 140NCT01621178
15 other results
  • -2.0 vs 1.1 0.75 mg · wk 26 · n 151 · Phase 3 · secondary NCT01621178
  • -1.7 vs 1.6 0.75 mg · wk 52 · n 137 · Phase 3 · secondary NCT01621178
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • -1.9 vs 2.4 wk 26 · n 349 · Phase 3 · secondary NCT02229227
  • -1.9 vs 2.4 wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • 1.3 vs 2.2 wk 26 · n 682 · Phase 3 · secondary NCT01468987
  • 1.0 vs 1.2 wk 24 · n 187 · Phase 3 · secondary NCT00666718
  • -2.0 vs 2.1 wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -1.7 vs 1.5 wk 10 · n 402 · Phase 3 · secondary NCT02229227
  • -0.9 vs 0.8 wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -0.6 vs 0.7 wk 4 · n 402 · Phase 3 · secondary NCT02229227
  • -2.7 vs 1.6 1.5 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • 0.3 vs 0.9 wk 16 · n 116 · Phase 3 · secondary NCT01474538
  • 1.3 vs 0.4 wk 16 · n 126 · Phase 4 · secondary NCT00393705
  • 2.6 vs 2.7 wk 48 · n 138 · Phase 4 · secondary NCT00664534

HbA1c below 7%

insulin aspart
44% vs 20%vs Metformin, Insulin Detemir, Insulin Aspartwk 26 · n 46NCT01966978
Insulin Lispro
37.5% vs 34.6%vs Insulin Glargine1.5 mg · wk 26 · n 152NCT01621178
3 other results
  • 32.9% vs 29.1% 1.5 mg · wk 52 · n 152 · Phase 3 · secondary NCT01621178
  • 31.7% vs 34.6% 0.75 mg · wk 26 · n 164 · Phase 3 · secondary NCT01621178
  • 33.5% vs 29.1% 0.75 mg · wk 52 · n 164 · Phase 3 · secondary NCT01621178

Fasting plasma glucose, change

insulin aspart
-1.8 vs -1.6vs Insulin Glarginewk 26 · n 283NCT04880850
5 other results
  • -3.0 vs -1.6 BID · wk 26 · n 354 · Phase 3 · secondary NCT02762578
  • -4.4 vs -3.0 wk 26 · n 195 · Phase 3 · secondary NCT01513590
  • -0.1 vs -1.2 wk 26 · n 86 · Phase 3 · secondary NCT01388361
  • -2 vs -4.4 twice daily · wk 4.14 · n 115 · Phase 3 · secondary NCT02648217
  • 6.4 vs 4.9 wk 26 · n 22 · Phase 4 · secondary NCT00998335
Insulin Lispro
-2.0 vs -1.5vs Insulin Lispro + Insulin Glarginewk 26 · n 345NCT02229227
4 other results
  • -2.0 vs -1.5 wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • -1.8 vs -1.2 wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1 vs -0.9 wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -1.3 vs -0.8 wk 4 · n 402 · Phase 3 · secondary NCT02229227

3-point MACE (% with event)

insulin aspart
—Not posted · NCT01467323
Insulin Lispro
—Not posted · NCT00551356
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety

Coverage. insulin aspart: 9 of 9 rows · Insulin Lispro: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin aspart
Rows use multiple source trials
Insulin Lispro
Rows use multiple source trials
BMI
absolute change · kg
0.2 vs 0.3 Insulin Detemir kg @ 26wka,b,c
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
-0.2 vs 1.01 Insulin Glargine kg @ 26wk1.5 mgd,a,b,c
NCT01191268 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.21 vs 1.01 Insulin Glargine kg @ 26wk0.75 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
HbA1c
absolute value · percentage points
6.7% (n=22) vs 6.9% (n=30) Insulin Detemir @ 26wka,b
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
6.76% (n=684) vs 6.97% (n=672) Insulin Glargine + Insulin Lispro @ 26wka,b
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
HbA1c
absolute change · percentage points
No placebo or comparator arm
-1.45% (n=136) @ 26wkd,e,b,c,f
NCT01680341 · Phase 3 · registry result, not featured evidence
show 1 more dose
-1.33% (n=136) @ 26wk
NCT01680341 · Phase 3 · registry result, not featured evidence
-0.48% (n=115)d,e,b,c,f
NCT01194258 · Phase 2 · registry result, not featured evidence
show 1 more dose
-0.46% (n=115)
NCT01194258 · Phase 2 · registry result, not featured evidence
HbA1c Less Than 7%
event count · % of participants
55.7% (n=361) vs 48.4% (n=182) BIAsp 30 @ 26wk*BIDg,b,c
Yes
NCT02762578 · Phase 3 · registry result, not featured evidence · converted to % from 201 Participants as posted
60.7% (n=402) vs 61.9% (n=412) Insulin Lispro + Insulin Glargine @ 26wk*d,g,b,c
NCT02229227 · Phase 3 · registry result, not featured evidence · combination · converted to % from 244 Participants as posted
show 1 more dose
60.7% (n=402) vs 61.9% (n=412) Insulin Lispro + Insulin Glargine @ 26wk*
NCT02229227 · Phase 3 · registry result, not featured evidence · combination · converted to % from 244 Participants as posted
Time Above Range
absolute value · % of time
30.47 vs 31.3 Insulin Glargine % of time @ 26wkb,c
NCT04880850 · Phase 3 · registry result, not featured evidence
40.1 vs 41.6 Insulin Glargine % of time @ 26wkb,c
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
Dropout rate
0%once weeklyh
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
show 24 more results
22%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
11.3%
NCT02453685 · Phase 4 · registry result, not featured evidence
13.9%
NCT01165684 · Phase 4 · registry result, not featured evidence
—
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00591227 · Phase 4 · registry result, not featured evidence
5.5%
NCT04880850 · Phase 3 · registry result, not featured evidence
2.2%
NCT02906917 · Phase 3 · registry result, not featured evidence
4.2%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
7.6%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
15.4%IDegAsp Simple
NCT01680341 · Phase 3 · registry result, not featured evidence
12.5%IDegAsp Step Wise
NCT01680341 · Phase 3 · registry result, not featured evidence
—
NCT01474538 · Phase 3 · registry result, not featured evidence
5.1%
NCT01513590 · Phase 3 · registry result, not featured evidence
13.6%
NCT01388361 · Phase 3 · registry result, not featured evidence · combination
6.6%IDegAsp Simple
NCT01365507 · Phase 3 · registry result, not featured evidence
6.4%IDegAsp Step Wise
NCT01365507 · Phase 3 · registry result, not featured evidence
6.8%OD
NCT01272193 · Phase 3 · registry result, not featured evidence
13.1%BID
NCT01059812 · Phase 3 · registry result, not featured evidence
18.1%once daily
NCT00972283 · Phase 3 · registry result, not featured evidence
15.5%once daily
NCT01045447 · Phase 3 · registry result, not featured evidence
17.7%
NCT01045707 · Phase 3 · registry result, not featured evidence
12.1%
NCT01009580 · Phase 3 · registry result, not featured evidence
—
NCT01194258 · Phase 2 · registry result, not featured evidence
3%
NCT00842361 · Phase 2 · registry result, not featured evidence
—i
NCT01474538 · Phase 3
show 18 more results
19.3%
NCT00664534 · Phase 4 · registry result, not featured evidence
15.2%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
4.7%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
12.7%
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
—1.5 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
—0.75 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
10.3%
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
19.7%1.5 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
18.8%0.75 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
—Glargine/Lispro
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
9.6%ILPS
NCT00666718 · Phase 3 · registry result, not featured evidence
—Lispro/Metformin
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
—Insulin Lispro (Lispro-PH20 Cohort
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Humalog + rHuPH20
NCT00916357 · Phase 2 · registry result, not featured evidence · combination
—Humalog Alone
NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy
—
NCT02197520 · Phase 1 · registry result, not featured evidence
11.1%
NCT05893797 · Phase na · registry result, not featured evidence
Discontinued due to AEs
—once weeklyh
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
show 24 more results
—
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02453685 · Phase 4 · registry result, not featured evidence
0.5%
NCT01165684 · Phase 4 · registry result, not featured evidence
—
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
—
NCT00591227 · Phase 4 · registry result, not featured evidence
—
NCT04880850 · Phase 3 · registry result, not featured evidence
0.4%
NCT02906917 · Phase 3 · registry result, not featured evidence
0.3%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
0%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
2.2%IDegAsp Simple
NCT01680341 · Phase 3 · registry result, not featured evidence
1.5%IDegAsp Step Wise
NCT01680341 · Phase 3 · registry result, not featured evidence
—
NCT01474538 · Phase 3 · registry result, not featured evidence
1%
NCT01513590 · Phase 3 · registry result, not featured evidence
5.7%
NCT01388361 · Phase 3 · registry result, not featured evidence · combination
—IDegAsp Simple
NCT01365507 · Phase 3 · registry result, not featured evidence
—IDegAsp Step Wise
NCT01365507 · Phase 3 · registry result, not featured evidence
0.7%OD
NCT01272193 · Phase 3 · registry result, not featured evidence
3.2%BID
NCT01059812 · Phase 3 · registry result, not featured evidence
4.1%once daily
NCT00972283 · Phase 3 · registry result, not featured evidence
0%once daily
NCT01045447 · Phase 3 · registry result, not featured evidence
1.9%
NCT01045707 · Phase 3 · registry result, not featured evidence
1.8%
NCT01009580 · Phase 3 · registry result, not featured evidence
—
NCT01194258 · Phase 2 · registry result, not featured evidence
—
NCT00842361 · Phase 2 · registry result, not featured evidence
—i
NCT01474538 · Phase 3
show 18 more results
1.8%
NCT00664534 · Phase 4 · registry result, not featured evidence
0%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
0.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
3.5%
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
—1.5 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
—0.75 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
1.7%
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
7.1%1.5 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
4.4%0.75 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
—Glargine/Lispro
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
0.5%ILPS
NCT00666718 · Phase 3 · registry result, not featured evidence
—Lispro/Metformin
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
—Insulin Lispro (Lispro-PH20 Cohort
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Humalog + rHuPH20
NCT00916357 · Phase 2 · registry result, not featured evidence · combination
—Humalog Alone
NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy
—
NCT02197520 · Phase 1 · registry result, not featured evidence
2.8%
NCT05893797 · Phase na · registry result, not featured evidence
Serious AEs
22.5%once weeklyh
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
show 24 more results
11.1%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
8.4%
NCT02453685 · Phase 4 · registry result, not featured evidence
9.1%
NCT01165684 · Phase 4 · registry result, not featured evidence
0%
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00591227 · Phase 4 · registry result, not featured evidence
7.6%
NCT04880850 · Phase 3 · registry result, not featured evidence
6.8%
NCT02906917 · Phase 3 · registry result, not featured evidence
4.4%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
3.8%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
5.2%IDegAsp Simple
NCT01680341 · Phase 3 · registry result, not featured evidence
7.5%IDegAsp Step Wise
NCT01680341 · Phase 3 · registry result, not featured evidence
11.8%
NCT01474538 · Phase 3 · registry result, not featured evidence
6.6%
NCT01513590 · Phase 3 · registry result, not featured evidence
4.6%
NCT01388361 · Phase 3 · registry result, not featured evidence · combination
0.7%IDegAsp Simple
NCT01365507 · Phase 3 · registry result, not featured evidence
4.3%IDegAsp Step Wise
NCT01365507 · Phase 3 · registry result, not featured evidence
3.4%OD
NCT01272193 · Phase 3 · registry result, not featured evidence
8.2%BID
NCT01059812 · Phase 3 · registry result, not featured evidence
18.5%once daily
NCT00972283 · Phase 3 · registry result, not featured evidence
4.3%once daily
NCT01045447 · Phase 3 · registry result, not featured evidence
11.3%
NCT01045707 · Phase 3 · registry result, not featured evidence
8.5%
NCT01009580 · Phase 3 · registry result, not featured evidence
6.5%
NCT01194258 · Phase 2 · registry result, not featured evidence
3%
NCT00842361 · Phase 2 · registry result, not featured evidence
12.7%i
NCT01474538 · Phase 3
show 18 more results
4.1%
NCT00664534 · Phase 4 · registry result, not featured evidence
2.2%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
6.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
5.8%
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
21.4%1.5 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
25.3%0.75 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
11.4%
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
9.2%1.5 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
15.7%0.75 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
4.8%Glargine/Lispro
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
—ILPS
NCT00666718 · Phase 3 · registry result, not featured evidence
7.5%Lispro/Metformin
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
0%Insulin Lispro (Lispro-PH20 Cohort
NCT01194258 · Phase 2 · registry result, not featured evidence
0%Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
4.5%Humalog + rHuPH20
NCT00916357 · Phase 2 · registry result, not featured evidence · combination
0%Humalog Alone
NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy
0%
NCT02197520 · Phase 1 · registry result, not featured evidence
8.3%
NCT05893797 · Phase na · registry result, not featured evidence
Most frequent reported AEs
once weeklyh
pain 17.5%
upper respiratory infection 0%
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
show 22 more results
gi 77.8%
headache 25.9%
other ae 7.4%
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 12.7%
headache 7.2%
arthralgia 6.6%
NCT02453685 · Phase 4 · registry result, not featured evidence
nasopharyngitis 8.1%
headache 5.1%
influenza 5.1%
NCT01165684 · Phase 4 · registry result, not featured evidence
covid-19 8.6%
diarrhoea 5.2%
diabetic retinopathy 4.1%
NCT04880850 · Phase 3 · registry result, not featured evidence
nasopharyngitis 13.6%
headache 10.2%
back pain 6%
NCT02906917 · Phase 3 · registry result, not featured evidence
BID
upper respiratory tract infection 21.1%
diabetic retinopathy 10%
viral upper respiratory tract infection 2.5%
NCT02762578 · Phase 3 · registry result, not featured evidence
twice daily
blood glucose decreased 35.4%
upper respiratory tract infection 6.2%
pyrexia 3.1%
NCT02648217 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 10.4%
nasopharyngitis 8.9%
headache 6.7%
NCT01680341 · Phase 3 · registry result, not featured evidence
nasopharyngitis 14.9%
influenza 9%
upper respiratory tract infection 7.5%
NCT01680341 · Phase 3 · registry result, not featured evidence
nasopharyngitis 4.2%
rhinitis allergic 4.2%
back pain 3.4%
NCT01474538 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.7%
NCT01513590 · Phase 3 · registry result, not featured evidence
nausea 20.7%
diarrhoea 10.3%
nasopharyngitis 10.3%
NCT01388361 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 9%
nasopharyngitis 6%
NCT01365507 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 10.7%
nasopharyngitis 7.9%
NCT01365507 · Phase 3 · registry result, not featured evidence
OD
nasopharyngitis 22.4%
diabetic retinopathy 5.4%
NCT01272193 · Phase 3 · registry result, not featured evidence
BID
nasopharyngitis 18.3%
upper respiratory tract infection 7.5%
diabetic retinopathy 6.8%
NCT01059812 · Phase 3 · registry result, not featured evidence
once daily
nasopharyngitis 16.5%
upper respiratory tract infection 16.3%
headache 9.4%
NCT00972283 · Phase 3 · registry result, not featured evidence
once daily
headache 8.7%
nasopharyngitis 7.4%
diarrhoea 5.2%
NCT01045447 · Phase 3 · registry result, not featured evidence
nasopharyngitis 13.6%
hypertension 7.5%
back pain 6%
NCT01045707 · Phase 3 · registry result, not featured evidence
nasopharyngitis 11.6%
upper respiratory tract infection 7.6%
headache 5.8%
NCT01009580 · Phase 3 · registry result, not featured evidence
uterine leiomyoma 6.7%
arthralgia 6.5%
headache 6.5%
NCT01194258 · Phase 2 · registry result, not featured evidence
nasopharyngitis 9.1%
supraventricular extrasystoles 6.1%
NCT00842361 · Phase 2 · registry result, not featured evidence
i
nasopharyngitis 4.2%
nausea 4.2%
fatigue 3.4%
NCT01474538 · Phase 3
show 17 more results
pyrexia 3.6%
neuropathy peripheral 3%
diarrhoea 2.4%
NCT00664534 · Phase 4 · registry result, not featured evidence
nasopharyngitis 4.3%
bronchitis 2.2%
arthralgia 1.4%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 6.3%
influenza 3.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
nausea 9.3%
diarrhoea 7.8%
viral upper respiratory tract infection 6.3%
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
1.5 mg
blood creatinine increased 38.5%
nausea 19.8%
diarrhoea 16.1%
NCT01621178 · Phase 3 · registry result, not featured evidence
0.75 mg
blood creatinine increased 37.4%
diarrhoea 15.8%
nausea 14.2%
NCT01621178 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.1%
upper respiratory tract infection 4.2%
diarrhoea 3.5%
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
1.5 mg
nausea 25.8%
diarrhea 14.9%
vomiting 11.9%
NCT01191268 · Phase 3 · registry result, not featured evidence
0.75 mg
nausea 17.7%
diarrhea 11.6%
vomiting 10.6%
NCT01191268 · Phase 3 · registry result, not featured evidence
nasopharyngitis 6.4%
headache 5.9%
diarrhoea 4.3%
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 5.3%
headache 4.8%
viral infection 3.7%
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 6.8%
headache 3.4%
influenza 3.4%
NCT01194258 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 11.9%
diarrhoea 8.5%
nasopharyngitis 5.1%
NCT01194258 · Phase 2 · registry result, not featured evidence
abdominal pain 4.5%
diarrhoea 4.5%
injection site pain 4.5%
NCT00916357 · Phase 2 · registry result, not featured evidence · combination
headache 13.6%
nausea 9.1%
abdominal pain 4.5%
NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy
catheter site related reaction 12.5%
upper respiratory tract infection 12.5%
urinary tract infection 12.5%
NCT02197520 · Phase 1 · registry result, not featured evidence
covid-19 8.3%
bronchitis 5.6%
dermatitis allergic 5.6%
NCT05893797 · Phase na · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 4 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eTrial phases differ: Phase 3 versus Phase 2.
  6. fThe assessment timepoint is not available for both results.
  7. gThe reported result categories differ.
  8. hPopulation comparability has not been reviewed for these studies.
  9. iPopulation comparability has not been reviewed for 18 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin aspart

HbA1c -0.5 vs 0 Insulin actual mean A1C change @ 26wkonce weekly
absolute change · actual mean A1C change
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
Treatment Failure 7.4% (n=46) vs 16.1% (n=44) Metformin, Insulin Detemir, Insulin Aspart @ 13wk
responder rate · % of participants
NCT01966978 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7 Without Severe Hypoglycemia 42.3% (n=168) vs 56.3% (n=167) insulin glargine + insulin aspart @ 32wk
responder rate · % of participants
NCT02453685 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7 19.2% (n=193) vs 56.3% (n=183) insulin aspart @ 10wk
absolute value · percentage points
NCT01165684 · Phase 4 · registry result, not featured evidence
show 2 more results
45.1% (n=195) vs 65.4% (n=188) insulin aspart @ 21wk
NCT01165684 · Phase 4 · registry result, not featured evidence
55.9% (n=195) vs 63.3% (n=188) insulin aspart @ 32wk
NCT01165684 · Phase 4 · registry result, not featured evidence
Fasting Plasma Glucose 7.1 vs 6.7 insulin aspart mmol/L @ 10wk
absolute value · mmol/L
NCT01165684 · Phase 4 · registry result, not featured evidence
show 2 more results
7.1 vs 7 insulin aspart mmol/L @ 21wk
NCT01165684 · Phase 4 · registry result, not featured evidence
7.12 vs 7.01 insulin aspart mmol/L @ 32wk
NCT01165684 · Phase 4 · registry result, not featured evidence
Postprandial Glucose Increment 2.3 vs 1.4 insulin aspart mmol/L @ 10wk
absolute value · mmol/L
NCT01165684 · Phase 4 · registry result, not featured evidence
show 2 more results
1.9 vs 1.5 insulin aspart mmol/L @ 21wk
NCT01165684 · Phase 4 · registry result, not featured evidence
1.64 vs 1.28 insulin aspart mmol/L @ 32wk
NCT01165684 · Phase 4 · registry result, not featured evidence
Body Weight 89.32 vs 89.8 insulin aspart kg @ 32wk
absolute value · kg
NCT01165684 · Phase 4 · registry result, not featured evidence
BMI 31.86 vs 32.03 insulin aspart kg @ 32wk
absolute value · kg
NCT01165684 · Phase 4 · registry result, not featured evidence
Hepatic Fat Fraction NA vs 6.7% (n=30) Insulin Detemir @ 13wk
percent change · % of baseline
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
5.9% (n=22) vs 8.4% (n=30) Insulin Detemir @ 26wk
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
Daily Plasma Glucose Change mg/dL NA vs 9.33 Insulin Detemir mmol/L @ 13wk
absolute change · mmol/L
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
9.44 vs 8.49 Insulin Detemir mmol/L @ 26wk*
NCT00998335 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from 170 mg/dL as posted
Time in Range 66.88 vs 66.44 Insulin Glargine % of time @ 26wk
absolute value · % of time
NCT04880850 · Phase 3 · registry result, not featured evidence
Hypoglycemia Episodes Level 3 7 vs 3 Insulin Glargine count @ 31wk
event count · count
NCT04880850 · Phase 3 · registry result, not featured evidence

+ 36 further endpoints in the CSV export.

Insulin Lispro

HbA1c Less Than 7% 30.3% (n=158) vs 24.2% (n=163) Glargine @ 16wk
responder rate · % of participants
Week 16 HbA1c <=7.0% (n=157, n=155)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 18.7% (n=158) vs 14.6% (n=163) Glargine @ 16wk
responder rate · % of participants
Week 16 HbA1c <=6.5% (n=157, n=155)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7% 37.6% (n=158) vs 32.1% (n=163) Glargine @ 32wk
responder rate · % of participants
Week 32 HbA1c <=7.0% (n=137, n=141)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 20.6% (n=158) vs 19% (n=163) Glargine @ 32wk
responder rate · % of participants
Week 32 HbA1c <=6.5% (n=137, n=141)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7% 48.2% (n=158) vs 36.2% (n=163) Glargine @ 48wk
responder rate · % of participants
Week 48 HbA1c <=7.0% (n=130, n=137)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 24.8% (n=158) vs 18.5% (n=163) Glargine @ 48wk
responder rate · % of participants
Week 48 HbA1c <=6.5% (n=130, n=137)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7% 21.4% (n=131) vs 18.5% (n=135) Insulin Biphasic Aspart 30/70 or Insulin Lispro LM @ 16wk
responder rate · % of participants
HbA1c <7%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
A1C Less Than 6 5 11.5% (n=131) vs 6.7% (n=135) Insulin Biphasic Aspart 30/70 or Insulin Lispro LM @ 16wk
responder rate · % of participants
HbA1c ≤6.5%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
PP 2 h Glucose mg/dL 163.4 vs 178.2 Insulin Biphasic Aspart 30/70 or Insulin Lispro LM mg @ 16wk
absolute value · mg
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
PPG 2 h Excursion mg/dL 17 vs 36.1 Insulin Biphasic Aspart 30/70 or Insulin Lispro LM mg @ 16wk
absolute value · mg
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
Fasting Plasma Glucose mg/dL 161.1 vs 153.9 Insulin Biphasic Aspart 30/70 or Insulin Lispro LM mg @ 16wk
absolute value · mg
Fasting
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7 Without Nocturnal Hypoglycemia 38.6% (n=361) vs 35.9% (n=362) Insulin Glargine @ 26wk
responder rate · % of participants
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
show 1 more result
23.7% (n=684) vs 12.2% (n=672) Insulin Glargine + Insulin Lispro @ 26wk
NCT01468987 · Phase 3 · registry result, not featured evidence · combination

+ 41 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin aspart's landscape · Insulin Lispro's landscape